Colon Cancer - Pipeline Review, H1 2016

Description: Colon Cancer - Pipeline Review, H1 2016

Summary

‘Colon Cancer - Pipeline Review, H1 2016’, provides an overview of the Colon Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colon Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Colon Cancer
- The report reviews pipeline therapeutics for Colon Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Colon Cancer therapeutics and enlists all their major and minor projects
- The report assesses Colon Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Colon Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Colon Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

Introduction
Colon Cancer Overview

Therapeutics Development
Colon Cancer - Therapeutics under Development by Companies
Colon Cancer - Therapeutics under Investigation by Universities/Institutes
Colon Cancer - Pipeline Products Glance
Colon Cancer - Products under Development by Companies
Colon Cancer - Products under Investigation by Universities/Institutes
Colon Cancer - Companies Involved in Therapeutics Development
Colon Cancer - Therapeutics Assessment

Drug Profiles
Colon Cancer - Dormant Projects
Colon Cancer - Discontinued Products
Colon Cancer - Product Development Milestones

Appendix
List of Tables
Number of Products under Development for Colon Cancer, H1 2016
Number of Products under Development for Colon Cancer - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Development by Companies, H1 2016 (Contd..2)
Number of Products under Development by Companies, H1 2016 (Contd..3)
Number of Products under Development by Companies, H1 2016 (Contd..4)
Number of Products under Development by Companies, H1 2016 (Contd..5)
Number of Products under Development by Companies, H1 2016 (Contd..6)
Number of Products under Development by Companies, H1 2016 (Contd..7)
Number of Products under Development by Companies, H1 2016 (Contd..8)
Number of Products under Development by Companies, H1 2016 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Development by Companies, H1 2016 (Contd..4)
Products under Development by Companies, H1 2016 (Contd..5)
Products under Development by Companies, H1 2016 (Contd..6)
Products under Development by Companies, H1 2016 (Contd..7)
Products under Development by Companies, H1 2016 (Contd..8)
Products under Development by Companies, H1 2016 (Contd..9)
Products under Development by Companies, H1 2016 (Contd..10)
Products under Development by Companies, H1 2016 (Contd..11)
Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
Colon Cancer - Pipeline by ACF Pharmaceuticals, LLC, H1 2016
Colon Cancer - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016
Colon Cancer - Pipeline by Aduro BioTech, Inc., H1 2016
Colon Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H1 2016
Colon Cancer - Pipeline by Advencen Laboratories, LLC, H1 2016
Colon Cancer - Pipeline by Agenus, Inc., H1 2016
Colon Cancer - Pipeline by AGV Discovery, SAS, H1 2016
Colon Cancer - Pipeline by AIMM Therapeutics B.V., H1 2016
Colon Cancer - Pipeline by Ambrx, Inc., H1 2016
Colon Cancer - Pipeline by Anavex Life Sciences Corp., H1 2016
Colon Cancer - Pipeline by AndroScience Corporation, H1 2016
Colon Cancer - Pipeline by Aphios Corporation, H1 2016
Colon Cancer - Pipeline by Aposense Ltd., H1 2016
Colon Cancer - Pipeline by Aptose Biosciences Inc., H1 2016
Colon Cancer - Pipeline by Asana BioSciences, LLC, H1 2016
Colon Cancer - Pipeline by AstraZeneca Plc, H1 2016
Colon Cancer - Pipeline by Aurigene Discovery Technologies Limited, H1 2016
Colon Cancer - Pipeline by BCN Biosciences L.L.C., H1 2016
Colon Cancer - Pipeline by Bio-Path Holdings, Inc., H1 2016
Colon Cancer - Pipeline by Biogazelle, H1 2016
Colon Cancer - Pipeline by Bioncotech Therapeutics S.L., H1 2016
Colon Cancer - Pipeline by Blirt S.A., H1 2016
Colon Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Colon Cancer - Pipeline by Can-Fite BioPharma Ltd., H1 2016
Colon Cancer - Pipeline by Celprogen, Inc., H1 2016
Colon Cancer - Pipeline by Celyad SA, H1 2016
Colon Cancer - Pipeline by Chiome Bioscience, Inc., H1 2016
Colon Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016
Colon Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
Colon Cancer - Pipeline by CytomX Therapeutics, Inc., H1 2016
Colon Cancer - Pipeline by Cytune Pharma SAS, H1 2016
Colon Cancer - Pipeline by CZ BioMed Corp, H1 2016
Colon Cancer - Pipeline by DEKK-TEC, Inc., H1 2016
Colon Cancer - Pipeline by Digna Biotech, S.L., H1 2016
Colon Cancer - Pipeline by Eli Lilly and Company, H1 2016
Colon Cancer - Pipeline by EntreChem, S.L., H1 2016
Colon Cancer - Pipeline by EnzymeBioSystems, H1 2016
Colon Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Colon Cancer - Pipeline by GlycaNova Norway AS, H1 2016
Colon Cancer - Pipeline by Halozyme Therapeutics, Inc., H1 2016
Colon Cancer - Pipeline by Heat Biologics, Inc., H1 2016
Colon Cancer - Pipeline by Helix BioPharma Corp., H1 2016
Colon Cancer - Pipeline by Histogen, Inc., H1 2016
Colon Cancer - Pipeline by Horizon Pharma Plc, H1 2016
Colon Cancer - Pipeline by Huperion Sarl, H1 2016
Colon Cancer - Pipeline by Idera Pharmaceuticals, Inc., H1 2016
Colon Cancer - Pipeline by Ignyta, Inc., H1 2016
Colon Cancer - Pipeline by Immunome Inc., H1 2016
Colon Cancer - Pipeline by Immunomedics, Inc., H1 2016
Colon Cancer - Pipeline by Immunotope, Inc., H1 2016
Colon Cancer - Pipeline by Immupharma Plc, H1 2016
Colon Cancer - Pipeline by IMPACT Therapeutics, Inc., H1 2016
Colon Cancer - Pipeline by Incuron, LLC, H1 2016
Colon Cancer - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016
Colon Cancer - Pipeline by Inflection Biosciences Limited, H1 2016
Colon Cancer - Pipeline by Innopharmax Inc., H1 2016
Colon Cancer - Pipeline by Intezyne, Inc, H1 2016
Colon Cancer - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016
Colon Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H1 2016
Colon Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2016
Colon Cancer - Pipeline by JW Pharmaceutical Corporation, H1 2016
Colon Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
Colon Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
Colon Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2016
Colon Cancer - Pipeline by Lipocure Ltd., H1 2016
Colon Cancer - Pipeline by LipoMedix Pharmaceutical Inc., H1 2016
Colon Cancer - Pipeline by Lupin Limited, H1 2016
Colon Cancer - Pipeline by Lymphocyte Activation Technologies, S.A., H1 2016
Colon Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016
Colon Cancer - Pipeline by MacroGenics, Inc., H1 2016
Colon Cancer - Pipeline by MaxiVAX SA, H1 2016
Colon Cancer - Pipeline by Meabco A/S, H1 2016
Colon Cancer - Pipeline by Molecular Targeting Technologies, Inc., H1 2016
Colon Cancer - Pipeline by Monopar Therapeutics LLC, H1 2016
Colon Cancer - Pipeline by Multimmune GmbH, H1 2016
Colon Cancer - Pipeline by NormOxys, Inc., H1 2016
Colon Cancer - Pipeline by Novartis AG, H1 2016
Colon Cancer - Pipeline by Omeros Corporation, H1 2016
Colon Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016
Colon Cancer - Pipeline by OncoVista Innovative Therapies, Inc., H1 2016
Colon Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
Colon Cancer - Pipeline by Orega Biotech SAS, H1 2016
Colon Cancer - Pipeline by OSE Immunotherapeutics, H1 2016
Colon Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016
Colon Cancer - Pipeline by PharmaCyte Biotech, Inc., H1 2016
Colon Cancer - Pipeline by Pharminox Limited, H1 2016
Colon Cancer - Pipeline by Philogen S.p.A., H1 2016
Colon Cancer - Pipeline by Pique Therapeutics, H1 2016
Colon Cancer - Pipeline by Plexxikon Inc., H1 2016
Colon Cancer - Pipeline by Provecs Medical GmbH, H1 2016
Colon Cancer - Pipeline by Proventis Biopharmaceuticals, Inc., H1 2016
Colon Cancer - Pipeline by Qu Biologics Inc., H1 2016
Colon Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
Colon Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016
Colon Cancer - Pipeline by Rgenix, Inc., H1 2016
Colon Cancer - Pipeline by Sareum Holdings Plc, H1 2016
Colon Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016
Colon Cancer - Pipeline by Sellas Inc., H1 2016
Colon Cancer - Pipeline by Sigma-Tau S.p.A., H1 2016
Colon Cancer - Pipeline by Sirnaomics, Inc., H1 2016
Colon Cancer - Pipeline by Somantix B.V., H1 2016
Colon Cancer - Pipeline by Sorrento Therapeutics, Inc., H1 2016
Colon Cancer - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016
Colon Cancer - Pipeline by Starpharma Holdings Limited, H1 2016
Colon Cancer - Pipeline by Synergys Biotherapeutics, Inc., H1 2016
Colon Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016
Colon Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016
Colon Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
Colon Cancer - Pipeline by Theryte Limited, H1 2016
Colon Cancer - Pipeline by Transgene Biotek Limited, H1 2016
Colon Cancer - Pipeline by TVAX Biomedical, Inc., H1 2016
Colon Cancer - Pipeline by Tyg Oncology Ltd., H1 2016
Colon Cancer - Pipeline by Vaccinogen, Inc., H1 2016
Colon Cancer - Pipeline by Vault Pharma Inc., H1 2016
Colon Cancer - Pipeline by Vaximm AG, H1 2016
Colon Cancer - Pipeline by VG Life Sciences, Inc., H1 2016
Colon Cancer - Pipeline by Yakult Honsha Co., Ltd., H1 2016
Colon Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016
Colon Cancer - Pipeline by ZIOPHARM Oncology, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Colon Cancer - Dormant Projects, H1 2016
Colon Cancer - Dormant Projects (Contd..1), H1 2016
Colon Cancer - Dormant Projects (Contd..2), H1 2016
Colon Cancer - Dormant Projects (Contd..3), H1 2016
Colon Cancer - Dormant Projects (Contd..4), H1 2016
Colon Cancer - Dormant Projects (Contd..5), H1 2016
Colon Cancer - Dormant Projects (Contd..6), H1 2016
Colon Cancer - Dormant Projects (Contd..7), H1 2016
Colon Cancer - Dormant Projects (Contd..8), H1 2016
Colon Cancer - Dormant Projects (Contd..9), H1 2016
Colon Cancer - Dormant Projects (Contd..10), H1 2016
Colon Cancer - Dormant Projects (Contd..11), H1 2016
Colon Cancer - Dormant Projects (Contd..12), H1 2016
Colon Cancer - Dormant Projects (Contd..13), H1 2016
Colon Cancer - Dormant Projects (Contd..14), H1 2016
Colon Cancer - Dormant Projects (Contd..15), H1 2016
Colon Cancer - Dormant Projects (Contd..16), H1 2016
Colon Cancer - Dormant Projects (Contd..17), H1 2016
Colon Cancer - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Colon Cancer, H1 2016
Number of Products under Development for Colon Cancer - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3775425/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Colon Cancer - Pipeline Review, H1 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3775425/">http://www.researchandmarkets.com/reports/3775425/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCPLXK55</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 5000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 7500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>________________________________</td>
</tr>
<tr>
<td>Email Address: *</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Job Title:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Organisation:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Address:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>City:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Country:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Phone Number:</td>
<td>___________________________________</td>
</tr>
<tr>
<td>Fax Number:</td>
<td>___________________________________</td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World